Lauréats Grants scientifiques 2020
Tous les deux ans, la Fondation contre le Cancer lance un appel à projets destiné aux chercheurs en oncologie, pour financer la recherche fondamentale, translationnelle et clinique. En 2020, 63 projets innovants et prometteurs, issus des diverses universités et institutions hospitalières du pays, ont été sélectionnés. Ils se sont partagés 23,8 millions d’euros.
Ce financement a été réparti comme suit:
- En recherche fondamentale : 30 projets sélectionnés pour un montant global de 13 284 989 €.
- En recherche translationnelle et clinique : 27 projets sélectionnés pour un montant global de 8 745 680 €.
- L’appel relatif aux cancers liés à l’exposition à l’amiante a permis de sélectionner 6 projets pour un montant global de 1 771 000 €.
Recherche fondamentale : 30 projets - 13 284 989 €
Équipe(s)
Institution(s)
Montant
Type de cancer
Type de traitement
Titre du projet
Aerts Stein
KU Leuven
578 000 €
OncoAI - a machine-learning framework to predict cancer cell vulnerability at the gene-regulatory level
Berx Geert
UGent
450 000 €
Cancer du sein
Defining the role of ZEB1 in tumour initiation and progression of basal-like breast cancer
Blanpain Cédric
ULB
720 000 €
Defining the mechanisms of clonal competition upon oncogenic transformation
Bollen Mathieu
KU Leuven
435 000 €
Phospho-regulation at the crossroads of cell proliferation and DNA-damage control
Carmeliet Geert
KU Leuven
462 000 €
Cancer du sein
Metabolic vulnerability of breast tumor cells during bone metastasis formation
Chariot Alain
ULiège
578 000 €
Cancer colorectal et cancer du sein
Oncogenic tRNA modifications and their targets
De Keermaecker Kim
KU Leuven
400 000 €
Leucémie
Traitement ciblé, chimiothérapie
Serine/glycine synthesis addiction in acute lymphoblastic leukemia and resulting therapeutic opportunities
De Preter Katleen
UGent
356 000 €
Neuroblastome
Characterizing regulatory heterogeneity in high-risk neuroblastoma
Detours Vincent
ULB
337 424 €
Cancer de la tyroïde & cancer du pancréas
Reappraisal of cancer morphology and its cellular and transcriptional determinants with unsupervised artificial intelligence, single nuclei and spatial transcriptomics
De Wever Olivier
UGent
400 000 €
Immunothérapie & radiothérapie
Impact of cancer-associated fibroblasts and their secretome on innate-adaptive immune cross-talk upon irradiation
Feron Olivier
UCLouvain
488 000 €
To reconcile the location of tumor microenvironment-driven mesenchymal-like cancer cells and their contribution to cancer progression.
Fuks François
ULB
569 000 €
Cancer du sein
Unravelling the role of epitranscriptomics in aggressive breast cancer by means of innovative technologies
Halder Georg
KU Leuven
570 800 €
Cancer du foie
Suppressing the evolution of liver cancer into highly aggressive forms
Jacquemin Patrick
UCLouvain
240 000 €
Cancer du pancréas
Identification of pancreatic cell types in the origin of human pancreatic cancer
Laoui Damya & Aboubakar Frank
VUB & UCLouvain
436 976 €
Cancer du poumon
Immunothérapie
cDC2s: new players in the tumor microenvironment and cancer immunotherapy
Lucas Sophie
UCLouvain
578 000 €
Immunothérapie
Deciphering molecular and cellular mechanisms of action of anti-GARP:TGF-β1 therapy
Mazzone Massimiliano
KU Leuven
542 000 €
Immunothérapie
Arachidonic acid metabolism, a cross point between "bad" and "good" macrophages in cancer: a novel therapeutic perspective?
Rapino Francesca
ULiège
337 500 €
“tRNA actors” heterogeneity: a new identifier of cancer stem cells
Swinnen Johan
KU Leuven
382 400 €
Cancer de la prostate
Exploiting acquired vulnerabilities in fatty acid metabolism to overcome therapy resistance in castration resistant prostate cancer
Tejpar Sabine
KU Leuven
337 500 €
Cancer colorectal
Immunothérapie
Coevolution of epithelium and immune response in colorectal cancer: comprehensive longitudinal analysis and manipulation of crosstalk leading to exhausted responses in dedicated mouse models.
Thienpont Bernard
KU Leuven
506 000 €
Cancer du poumon
Inhibiting resistance acquisition by epigenetically altering tumour heterogeneity
Vandenabeele Peter
UGent
360 000 €
Cancer colorectal
Immunothérapie
Improving cancer therapy by modulating cell death and the microbiome in the gut
Van den Broeke Anne & Georges Michel
Institut Bordet & ULiège
448 000 €
Leucémie
Tracking tumor evolution and drivers of oncogenic switch: lessons from single cells, viruses and sheep
Van Ginderachter Jo
VUB
445 991 €
Immunothérapie
Selective elimination of tumor-infiltrating regulatory T cells via IL-1R2 targeting
Van Gastel Nick
Institut de Duve
480 000 €
Leucémie
Understanding metabolic crosstalk in the leukemic bone marrow niche
Recherche translationnelle et clinique :
27 projets - 8 745 680 €
Équipe(s)
Institution(s)
Montant
Type de cancer
Type de traitement
Titre du projet
Albersen Maarten
KU Leuven
395 000 €
Cancer du pénis
Traitement ciblé
Developing personalized treatment for advanced penile cancer trough establishment of Patient-Derived Tumor Xenografts (PDTXs).
Berx Geert
UGent
399 920 €
Cancer du côlon
Traitement ciblé
Preclinical validation of novel plastistatic therapy for malignant colon cancer
Borbath Ivan, Peeters Marc, Van Laethem Jean-Luc & Van Cutsem Eric
UC Louvain, UAntwerpen, ULB - Erasme & KU Leuven
398 000 €
Cancer de la vésicule biliaire
Traitement ciblé
SAFIR-ABC10: molecular screening for precision medicine in advanced biliary cancers
Bormans Guy
KU Leuven
325 000 €
Radiothérapie
Peptide based CXCR4 targetting for PET imaging and radionuclide therapy
Caers Jo
ULiège
380 000 €
Myélome multiple
Immunothérapie
Novel antigen identification for multiple myeloma
Cools Jan
KU Leuven
400 000 €
Leucémie
Traitement ciblé
PSEN1-selective gamma-secretase inhibition for the treatment of T-cell acute lymphoblastic leukemia
Creytens David & Hernot Sophie
UGent & VUB
86 500 €
Chirurgie
Peroperative ex vivo cancer margin detection using fluorescence labelled single-domain antibodies
De Neve Wilfried, Van Gestel Dirk & Remouchamps Vincent
UGent & ULB & CHU Namur - UCLouvain
400 000 €
Cancer du sein
Radiothérapie
Maximizing the ratio of radiotherapy survival benefit over radiation-related morbidity and mortality in patients requiring breast and regional lymph nodes treatment. A multicenter study using the prone crawl radiotherapy technique
Desmedt Christine, Vermeulen Peter, Donckier de Donceel Vincent
KU Leuven & U Antwerpen & ULB, Bordet
399 125 €
Cancer du sein et métastases hépatiques
Clinical, experimental and molecular characterization of liver metastases from breast cancer patients.
Flamen Patrick
ULB, Bordet
299 920 €
Cancer du poumon
Radiothérapie & immunothérapie
Molecular imaging of cancer-associated fibroblasts in NSCLC treated with immune-checkpoint inhibitors.
Gallez Bernard
UCLouvain
250 000 €
Cancer de la peau
Characterization of skin melanomas by Electron Paramagnetic Resonance
Humblet-Baron Stéphanie
UGent
390 000
Leucémie et lymphome
Immunothérapie
In-depth investigation of patient immune signature after CD19 CAR T-cell therapy
Kridelka Frédéric
ULiège
200 000 €
Cancer du col de l'utérus
Lymph node profiling in advanced cervical cancer
Lambrechts Diether
KU Leuven
379 960 €
Immunothérapie
Alternative RNA splicing as a predictor of response to checkpoint immunotherapy
Nuyts Sandra
KU Leuven
400 000 €
Cancer de la zone tête et cou
Radiothérapie
Prediction of RT response in head and neck cancers by assessment of the clonal repopulation dynamics
Piccart Martine
ULB, Bordet
400 000 €
Cancer du sein
AURORA - Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer
Sotiriou Christos
Institut Jules Bordet
238 000 €
Cancer du sein
Mapping tumor and immune cell architecture in TNBC using spatial transcriptomics and single nuclei sequencing
Speleman Franki
UGent
200 000 €
Neuroblastome
Traitement ciblé
Scrutinizing selective Aurora kinase A inhibition as a novel therapeutic strategy for neuroblastoma
Sprangers Ben
KU Leuven
345 000 €
Immunothérapie
Developing approaches to allow the safe and effective use of checkpoint inhibitors in solid organ transplant patients
Taghon Tom
UGent
380 000 €
Cancer du thymus
Functional characterization and expansion of thymus seeding precursors in human.
Topal Baki
UZ Leuven
200 000 €
Cancer du pancréas
Immunothérapie
Effects of immunotherapy on the cellular landscape and immune milieu in locally advanced pancreatic ductal adenocarcinoma
Van den Eynde Marc, Carrasco Javier, Liberale Gabriele & Raes Jeroen
UCLouvain, GHdC, Institut Jules Bordet & KU Leuven
399 252 €
Cancer du côlon
Immunothérapie
The microbiome in colorectal metastases: nature and impact on local immune and inflammatory response, disease evolution and response to therapy
Vandekerckhove Bart
UGent
365 145 €
Cancer du poumon
Immunothérapie
Improving Neo-epitope Identification in lung cancer patients using Mass spectrometry and Next generation sequencing (INI-M&N)
Van Craenenbroeck Emeline
UAntwerpen
382 900 €
Cancer du sein
Discovering the role of titin (TTN) in anthracycline-induced cardiac dysfunction in breast cancer
Vanhaudenhuyse Audrey
ULiège
399 935 €
Hypnose
Hypnosis and cognitive trance on cancer patients: impact on quality of life and neurophysiology
Wildiers Hans
KU Leuven
100 000 €
Cancer du sein
Mechanisms involved in metastasis of luminal breast cancer
Amiante : 6 projets - 1 771 000 €
Équipe(s)
Institution(s)
Montant
Thématique
Titre du projet
Feron Olivier
UCLouvain
400 000 €
Mésothéliome & immunothérapie
In situ induction of immunogenic cell death to boost DC-based immunotherapy of peritoneal mesothelioma
Halder Georg
KU Leuven
400 000 €
Mésothéliome & traitement ciblé
Understanding the anti-cancer effects of new YAP/TAZ inhibitors to treat malignant mesothelioma
Janssens Veerle
KU Leuven
325 000 €
Mésothéliome
Protein Phosphatase 2A dysfunctions in malignant pleural mesothelioma: oncogenic mechanisms and therapeutic opportunities
Lion Eva, Germonpré Paul & Valcke Yvan
U Antwerpen & AZ Middelares & AZ Niklaas
200 000 €
Mésothéliome & immunothérapie
Boosting the response rate to standard treatment with upfront dendritic cell vaccination in patients with malignant pleural mesothelioma
Van Camp Guido
UAntwerpen
223 000 €
Mésothéliome
Towards a novel generation detection biomarkers for malignant pleural mesothelioma in clinical practice
